Oxford BioMedica (LSE:OXB) Cash-to-Debt : 0.93 (As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Oxford BioMedica Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Oxford BioMedica's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.93.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Oxford BioMedica couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Oxford BioMedica's Cash-to-Debt or its related term are showing as below:

LSE:OXB' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.34 Med: 1.08 Max: 14.2
Current: 0.93

During the past 13 years, Oxford BioMedica's highest Cash to Debt Ratio was 14.20. The lowest was 0.34. And the median was 1.08.

LSE:OXB's Cash-to-Debt is ranked worse than
78.24% of 1535 companies
in the Biotechnology industry
Industry Median: 6.49 vs LSE:OXB: 0.93

Oxford BioMedica Cash-to-Debt Historical Data

The historical data trend for Oxford BioMedica's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Oxford BioMedica Cash-to-Debt Chart

Oxford BioMedica Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

2.26

3.39

11.67

1.24

0.93

Oxford BioMedica Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															11.67	1.10	1.24	1.14	0.93

Competitive Comparison of Oxford BioMedica's Cash-to-Debt

For the Biotechnology subindustry, Oxford BioMedica's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oxford BioMedica's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxford BioMedica's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Oxford BioMedica's Cash-to-Debt falls into.

Oxford BioMedica Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Oxford BioMedica's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	103.716	/	(3.654	+	107.804)
	=	0.93

Oxford BioMedica's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	103.716	/	(3.654	+	107.804)
	=	0.93

Oxford BioMedica (LSE:OXB) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Oxford BioMedica Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Oxford BioMedica's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Oxford BioMedica (LSE:OXB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford BioMedica PLC (LSE:OXB) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

OXBDF:USA OXBl:UK OXO:Germany

Address

Windrush Court, Transport Way, Oxford, GBR, OX4 6LT

Website

https://www.oxb.com

Oxford BioMedica PLC is a player in the healthcare market in the United Kingdom. As a biopharmaceutical company, it focuses on the field of immunotherapy by managing a platform of technologies for designing gene-based medicines. The company's operating segments include the Platform segment consists of the revenue-generating bioprocessing and process development activities undertaken for third parties. Its Product segment consists of the clinical and preclinical development of in vivo and ex vivo gene and cell therapy products. The company derives the maximum revenue from the Platform segment. Its Platform includes LentiVector, LentiStable, TRiPSystem, SecNuc, Analytics, and others. Geographically, it generates the majority of its revenue from Europe.

Oxford BioMedica (LSE:OXB) Headlines

No Headlines